96 Tests PN: B114578

Components:

45x Ab-conjugated beads (S4P9 - human NOV Ab-bead). PN: B114578A. One vial containing 100 µL of anti-human NOV conjugated to AimPlex Bead S4P9.

25x Biotin-detection Ab (human NOV Biotin-dAb). PN: B114578B. One vial containing 100 µL of biotinylated anti-human NOV.

Lyophilized Standard Mix-Human Group 10, Panel B, 7-Plex. PN: HG1007B. One vial containing lyophilized recombinant Lymphotactin, MIA, Midkine, NOV, NRG1-beta1, sTACI, and sTRAIL. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

Application: Optimal antibody pair and antigen standard for assaying human Human NOV/CCN3/IGFBP-9. Can be multiplexed with other analytes in Human Group 10.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 5 pg/mL

  • Quantitation range:

  • LLOQ: < 10 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Human Group 10: Negligible

  • Sample volume: 15 µL/test

Description:

NOV (nephroblastoma overexpressed) also known as CCN3 and Insulin-Like Growth Factor-Binding Protein 9 (IGFBP-9)  is a matricellular protein that in humans is a member of the CCN family of secreted, extracellular matrix (ECM)-associated signaling proteins. The CCN acronym is derived from the first three members of the family being identified, namely CYR61 (cysteine-rich angiogenic inducer 61, or CCN1), CTGF (connective tissue growth factor, or CCN2), and NOV. NOV regulates multiple cellular activities including cell adhesion, migration, proliferation, differentiation, and survival. It functions by direct binding to integrin receptors, as well as other receptors such as NOTCH1 and fibulin 1c (FBLN1). NOV is expressed during wound healing and induces angiogenesis in vivo.  It is essential for self-renewal of CD34+ hematopoietic stem cells from umbilical cord blood. NOV can bind BMP2 and inhibit its functions in promoting osteogenic differentiation, and stimulate osteoclastogenesis through a process that may involve calcium flux. Diseases associated with NOV include Wilms Tumor.

References:

  1. Martinerie C, Viegas-Pequignot E, Guenard I, Dutrillaux B, Nguyen VC, Bernheim A, Perbal B (Dec 1992). "Physical mapping of human loci homologous to the chicken nov proto-oncogene". Oncogene 7 (12): 2529–34. PMID 1334251.

  2. "Entrez Gene: NOV nephroblastoma overexpressed gene".

  3. Jun JI, Lau LF (Dec 2011). "Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets". Nature Reviews. Drug Discovery 10 (12): 945–63. doi:10.1038/nrd3599. PMID 22129992.

  4. Lin CG, Leu SJ, Chen N, Tebeau CM, Lin SX, Yeung CY, Lau LF (Jun 2003). "CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family". The Journal of Biological Chemistry 278 (26): 24200–8. doi:10.1074/jbc.M302028200. PMID 12695522.